GSK Plc’s experimental drug to treat a common inflammatory nasal condition showed positive results in two late-stage trials ...

The Biden administration has reformed Medicare, gone after bogus drug patents and pushed pharmaceutical companies to reduce ...

Artificial intelligence chatbots cannot be relied on to give accurate, safe or even clear advice about medication, according ...

Moreover, diabetes was linked with a nearly fourfold increase in pulmonary fibrosis among patients with RA (OR 3.704, 95% CI ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the ...

Depemokimab has already shown its potential as a therapy for severe asthma in two other phase 3 trials – SWIFT-1 and SWIFT-2 ...

GSK announced another batch of positive data from its respiratory program with the investigational drug depemokimab, this ...

The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.

GSK plc (LSE/NYSE: GSK) has released new data from the AReSVi-006 Phase III trial, demonstrating the efficacy and safety of ...

GSK & ViiV Healthcare to showcase advances across industry-leading infectious disease portfolio at IDWeek 2024: London, UK Monday, October 14, 2024, 14:00 Hrs [IST] GSK plc and Vi ...

These FTSE shares don’t have the highest yields. But Edward Sheldon believes they could deliver attractive returns in the ...

GSK announced positive results from two phase 3 clinical trials evaluating its experimental drug, depemokimab, for chronic rhinosinusitis with nasal polyps affecting 4% of the population.